Skip to main content

Advertisement

SpringerLink
Log in

Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?

  • Fatty Liver Disease (SA Harrison and J George, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Non-alcoholic fatty liver disease affects nearly 30 % of Americans. A histopathological spectrum exists from simple steatosis to NASH which may progress to cirrhosis and HCC. NASH is currently the third most common indication for liver transplant with increasing incidence. Steatosis can be considered the hepatic manifestation of the metabolic syndrome as insulin resistance is a major risk factor for its development. While liver biopsy is the gold standard for diagnosis, non-invasive methods are currently being developed to appropriately determine who needs histologic evaluation. Management focuses on mitigation of risk factors, since targeted therapies to halt progression of fibrosis have not been validated. Simple steatosis does not affect overall survival, but NASH conveys increased mortality. Because of this, non-invasive strategies to diagnose patients and management algorithms are needed. This review supports the definitions of simple steatosis and NASH as two distinct entities based on pathophysiology, diagnosis, management, and prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883–9.

    Article  CAS  PubMed  Google Scholar 

  2. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38.

    Article  CAS  PubMed  Google Scholar 

  3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95.

    Article  PubMed  Google Scholar 

  4. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.

    Article  PubMed  Google Scholar 

  5. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.

    Article  CAS  PubMed  Google Scholar 

  6. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;14(4):1249–53. This paper showed NASH is on a trajectory to become the most common indication for liver transplantation.

    Article  Google Scholar 

  7. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.

    CAS  PubMed  Google Scholar 

  8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.

    Article  CAS  PubMed  Google Scholar 

  9. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007 Feb;11(1):105–17, ix.

  10. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res. 2013;43(1):51–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Lottenberg AM, Afonso Mda S, Lavrador MS, Machado RM, Nakandakare ER. The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem. 2012;23(9):1027–40.

    Article  CAS  PubMed  Google Scholar 

  12. Sevastianova K, Santos A, Kotronen A, et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr. 2012;96(4):727–34.

    Article  CAS  PubMed  Google Scholar 

  13. Guglielmi FW, Boggio-Bertinet D, Federico A, et al. Total parenteral nutrition-related gastroenterological complications. Dig Liver Dis. 2006;38(9):623–42.

    Article  CAS  PubMed  Google Scholar 

  14. Naini BV, Lassman CR. Total parenteral nutrition therapy and liver injury: a histopathologic study with clinical correlation. Hum Pathol. 2012;43(6):826–33.

    Article  CAS  PubMed  Google Scholar 

  15. Anthérieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology. 2011;53(6):1895–905.

    Article  PubMed  Google Scholar 

  16. Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12(5):e32–43.

    Article  CAS  PubMed  Google Scholar 

  17. Abenavoli L, Milic N, De Lorenzo A, Luzza F. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine. 2013;43(1):65–7.

    Article  CAS  PubMed  Google Scholar 

  18. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114(4):842–5.

    Article  CAS  PubMed  Google Scholar 

  19. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46.

    Article  CAS  PubMed  Google Scholar 

  20. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25(4):672–90.

    Article  CAS  PubMed  Google Scholar 

  21. Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr. 2011;53(2):131–40.

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375(9733):2267–77.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969–74.

    Article  PubMed  Google Scholar 

  24. Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013. doi:10.1016/j.jhep.2013.04.027.

    Google Scholar 

  25. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132–8.

    Article  PubMed  Google Scholar 

  26. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology. 2010;51(2):373–5.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36(9):815–23. Excellent review article defining simple steatosis and NASH as separate pathophysiological entities.

    CAS  PubMed  Google Scholar 

  28. Newton JL, Jones DE, Henderson E, et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008;57(6):807–13.

    Article  CAS  PubMed  Google Scholar 

  29. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609. Practice guidelines providing insight into the diagnosis and management of NAFLD for general practitioners and specialists..

    Article  PubMed  Google Scholar 

  30. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93(1):44–8.

    Article  CAS  PubMed  Google Scholar 

  31. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356–62.

    Article  CAS  PubMed  Google Scholar 

  32. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.

    Article  CAS  PubMed  Google Scholar 

  33. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617–49.

    Article  PubMed  Google Scholar 

  34. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57(4):1357–65. An outstanding analysis of a sample representative of the general United States population determining both the prevalence of advanced fibrosis and the accuracy of the NAFLD fibrosis score in predicting long-term mortality..

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219–29.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomens of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782–9. Study demonstrating the high accuracy of the NAFLD fibrosis score in predicting long-term risk to develop liver-related complications and overall mortality in patients with NAFLD..

    Article  PubMed  Google Scholar 

  37. Grattagliano I, Ubaldi E, Napoli L, et al. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study. Ann Hepatol. 2013;12(1):70–7.

    PubMed  Google Scholar 

  38. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2013. doi:10.1111/hepr.12197Meta-analysis showing CK-18 fragments are a useful non-invasive way to screen for NASH. ..

    Google Scholar 

  39. Grandison GA, Angulo P. Can NASH be diagnosed, graded and staged noninvasively? Clin Liver Dis. 2012;16(3):567–85.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10(11):666–75. An thorough review of the available noninvasive tools to evaluate patients with NAFLD..

    Article  CAS  PubMed  Google Scholar 

  41. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 2013;268(2):411–9.

    Article  PubMed  Google Scholar 

  42. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011;259(3):749–56.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.

    Article  PubMed  Google Scholar 

  44. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Fukusato T, Fukushima J, Shiga J, et al. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res. 2005;33(2):122–7.

    Article  PubMed  Google Scholar 

  46. Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg. 2005;15(4):497–501.

    Article  PubMed  Google Scholar 

  47. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898–906.

    Article  PubMed  Google Scholar 

  48. Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28(1):40–51.

    Article  PubMed  Google Scholar 

  49. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51(1):89–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100(5):1072–81.

    Article  PubMed  Google Scholar 

  51. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Rodriguez B, Torres DM, Harrison SA. Physical activity: an essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9(12):726–31.

    Article  PubMed  Google Scholar 

  53. Hattar LN, Wilson TA, Tabotabo LA, Smith EO, Abrams SH. Physical activity and nutrition attitudes in obese Hispanic children with non-alcoholic steatohepatitis. World J Gastroenterol. 2011;17(39):4396–403.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106(3):460–8. quiz 469.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.

    Article  CAS  PubMed  Google Scholar 

  56. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. Curr Pharm Des. 2013;19(29):5177–92.

    Article  CAS  PubMed  Google Scholar 

  57. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9(7):372–81.

    Article  CAS  PubMed  Google Scholar 

  58. Treeprasertsuk S, Leverage S, Adams LA, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012;32(6):945–50.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2013;58(4):757–62.

    Article  PubMed  Google Scholar 

  60. Nseir W, Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Curr Atheroscler Rep. 2013;15(3):305.

    Article  PubMed  Google Scholar 

  61. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–32. Statin use decreased the likelihood of developing HCC by an adjusted odds ratio of 0.63.

    Article  CAS  PubMed  Google Scholar 

  62. Yilmaz Y, Colak Y, Kurt R, Senates E, Eren F. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back. Tumori. 2013;99(1):10–6.

    CAS  PubMed  Google Scholar 

  63. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–307.

    Article  CAS  PubMed  Google Scholar 

  64. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176–84.

    Article  CAS  PubMed  Google Scholar 

  65. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Haukeland JW, Konopski Z, Eggesbø HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853–60.

    Article  CAS  PubMed  Google Scholar 

  67. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  68. Klein EA, Thompson Jr IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.

    Article  CAS  PubMed  Google Scholar 

  69. Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.

    Article  CAS  PubMed  Google Scholar 

  70. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54(5):1610–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  71. Ku CS, Yang Y, Park Y, Lee J. Health benefits of blue-green algae: prevention of cardiovascular disease and nonalcoholic fatty liver disease. J Med Food. 2013;16(2):103–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  72. Gutiérrez-Grobe Y, Chávez-Tapia N, Sánchez-Valle V, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol. 2012;11(3):350–5.

    PubMed  Google Scholar 

  73. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35(1):76–82.

    Article  CAS  PubMed  Google Scholar 

  74. Shavakhi A, Minakari M, Firouzian H, et al. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Int J Prev Med. 2013;4(5):531–7.

    PubMed Central  PubMed  Google Scholar 

  75. Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012;57(2):384–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Moriya A, Iwasaki Y, Ohguchi S, et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33(3):378–88.

    Article  CAS  PubMed  Google Scholar 

  77. Völzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol. 2012;18(27):3492–501.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–9.

    Article  CAS  PubMed  Google Scholar 

  79. Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602.

    Article  PubMed  Google Scholar 

  80. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53(5):750–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73.

    Article  CAS  PubMed  Google Scholar 

  82. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714–9.

    Article  CAS  PubMed  Google Scholar 

  83. Charatcharoenwitthaya P, Lindor KD, Angulo P. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(7):1925–31.

    Article  CAS  PubMed  Google Scholar 

  84. Merat S, Sotoudehmanesh R, Nouraie M, et al. Sampling error in histopathology findings of nonalcoholic fatty liver disease: a post mortem liver histology study. Arch Iran Med. 2012;15(7):418–21.

    PubMed  Google Scholar 

  85. Ekstedt M, Franzén LE, Mathiesen UL, Kechagias S. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. Scand J Gastroenterol. 2012;47(1):108–15.

    Article  PubMed  Google Scholar 

  86. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54(4):1208–16.

    Article  PubMed Central  PubMed  Google Scholar 

  87. Singal AK, Guturu P, Hmoud B, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95(5):755–60.

    Article  PubMed  Google Scholar 

  88. Agopian VG, Kaldas FM, Hong JC, et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg. 2012;256(4):624–33.

    Article  PubMed  Google Scholar 

  89. Dureja P, Mellinger J, Agni R, et al. NAFLD recurrence in liver transplant recipients. Transplantation. 2011;91(6):684–9. NAFLD recurred in 39% of patients after liver transplant, but survival was not affected..

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Cory M. Fielding declares no conflicts of interest.

Paul Angulo declares no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Kentucky, 304B Charles T. Wethington Bldg. 900 South Limestone, Lexington, KY, 40536-0200, USA

    Cory M. Fielding

  2. Division of Digestive Diseases and Nutrition, Department of Internal Medicine, University of Kentucky, 800 Rose Street, Room MN649, Lexington, KY, 40536-0298, USA

    Paul Angulo

Authors
  1. Cory M. Fielding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Angulo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Angulo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fielding, C.M., Angulo, P. Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?. Curr Hepatology Rep 13, 151–158 (2014). https://doi.org/10.1007/s11901-014-0227-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-014-0227-5

Keywords

Search

Navigation